In the new VEXAS syndrome study, publishing in the Journal of the American Medical Association (JAMA) online Jan. 24, researchers analyzed the electronic health records of 163,096 mostly white men and women in Pennsylvania who agreed to have their blood DNA screened for signs of genetic disease. Twelve were found to have the UBA1 mutation, with all experiencing VEXAS symptoms.

David Jenkins, Ra Medical Systems Executive Chairman. “All four abstracts with VIVO clinical data submitted by leading physicians to the Congress were accepted for presentation following an extensive peer-review process. To have one-hundred percent acceptance of submitted abstracts is rare and I believe indicative of the positive impact VIVO is having on ventricular ablation procedures. We view this recognition as a major milestone in gaining clinical acceptance by both EP thought leaders and the larger medical community.”

Vasc-Alert, a pioneer in vascular access surveillance, today announced the publication of a study in the Journal of Vascular Access validating its Vasc-Alert surveillance technology

Updated results from the CHOPIN Phase 1b Trial in seven patients with advanced uveal melanoma treated with CHEMOSAT and ipilimumab plus nivolumab show a Median PFS of 29.1 months

Severe inflammation weakens the body’s ability to kill cancerous blood cells in people with acute myeloid leukemia (AML), a new study shows.